Skip to content

Released Mar 15, 2023, before the open

10-K filed Mar 15, 2023, 74 days after period end · 0001171843-23-001691

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$11.59MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$12,888,000N/M
Operating Cash Flowderived-$10,641,000N/M
Free Cash Flowderived-$10,695,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019
Net Income-$11.59M-$12.98M-$8.39M-$11.68K
EPS Diluted———$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR